Evidence map›Paper›PMID 38774585›Full record

ArticleBeilstein journal of nanotechnology2024

On the additive artificial intelligence-based discovery of nanoparticle neurodegenerative disease drug delivery systems.

Shan He, Julen Segura Abarrategi, Harbil Bediaga, Sonia Arrasate, Humberto González-Díaz

Abstract read
In one paragraph

Article in Beilstein journal of nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Nanoinformatics: spanning scales, systems and solutions.Beilstein journal of nanotechnology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shan HeDepartment of Organic and Inorganic Chemistry, University of Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID https://orcid.org/0000-0001-6965-6276
Julen Segura AbarrategiDepartment of Organic and Inorganic Chemistry, University of Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID https://orcid.org/0009-0006-3098-5543
Harbil BediagaIKERDATA S.L., ZITEK, UPV/EHU, Rectorate Building, nº6, 48940 Leioa, Greater Bilbao, Basque Country, Spain.ORCID https://orcid.org/0000-0002-9055-0721
Sonia ArrasateDepartment of Organic and Inorganic Chemistry, University of Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID https://orcid.org/0000-0003-2601-5959
Humberto González-DíazDepartment of Organic and Inorganic Chemistry, University of Basque Country UPV/EHU, 48940 Leioa, Spain.ORCID https://orcid.org/0000-0002-9392-2797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases are characterized by slowly progressing neuronal cell death. Conventional drug treatment strategies often fail because of poor solubility, low bioavailability, and the inability of the drugs to effectively cross the blood-brain barrier. Therefore, the development of new neurodegenerative disease drugs (NDDs) requires immediate attention. Nanoparticle (NP) systems are of increasing interest for transporting NDDs to the central nervous system. However, discovering effective nanoparticle neuronal disease drug delivery systems (N2D3Ss) is challenging because of the vast number of combinations of NP and NDD compounds, as well as the various assays involved. Artificial intelligence/machine learning (AI/ML) algorithms have the potential to accelerate this process by predicting the most promising NDD and NP candidates for assaying. Nevertheless, the relatively limited amount of reported data on N2D3S activity compared to assayed NDDs makes AI/ML analysis challenging. In this work, the IFPTML technique, which combines information fusion (IF), perturbation theory (PT), and machine learning (ML), was employed to address this challenge. Initially, we conducted the fusion into a unified dataset comprising 4403 NDD assays from ChEMBL and 260 NP cytotoxicity assays from journal articles. Through a resampling process, three new working datasets were generated, each containing 500,000 cases. We utilized linear discriminant analysis (LDA) along with artificial neural network (ANN) algorithms, such as multilayer perceptron (MLP) and deep learning networks (DLN), to construct linear and non-linear IFPTML models. The IFPTML-LDA models exhibited sensitivity (Sn) and specificity (Sp) values in the range of 70% to 73% (>375,000 training cases) and 70% to 80% (>125,000 validation cases), respectively. In contrast, the IFPTML-MLP and IFPTML-DLN achieved Sn and Sp values in the range of 85% to 86% for both training and validation series. Additionally, IFPTML-ANN models showed an area under the receiver operating curve (AUROC) of approximately 0.93 to 0.95. These results indicate that the IFPTML models could serve as valuable tools in the design of drug delivery systems for neurosciences.

Indexed as

artificial neural network (ANN)linear discriminant analysis (LDA)machine learningnanoparticleneurodegenerative diseases

Identifiers

PMID38774585
PMCPMC11106676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.